How are lateral flow immunoassay devices classified under EU IVDR? CE Marking Guide

Under today’s rules, lateral flow immunoassay IVDs are classified under the In Vitro Diagnostic Medical Devices Regulation (IVDR) 2017/746 into four risk classes—A, B, C, and D—not the “Class 1” often cited. The “self‑certification” pathway you are asking about still exists, but it only applies to Class A devices, and almost no finished lateral flow test kits qualify for it. If your device is a pregnancy test, drug screen strip, or similar, it will almost certainly be Class B or higher, requiring a Notified Body review—not a simple self‑declaration.

While many legacy materials describe a “Class 1” self‑certification route for simple lateral flow tests, that language reflects the old IVD Directive (IVDD) landscape. Under the current IVDR, the classification and conformity assessment have shifted significantly. Knowing exactly where your product lands and which pathway applies is the only way to avoid costly regulatory delays or non‑compliance.

The European IVD Regulatory Framework: From Directives to Regulations

Understanding the IVDR Classification System

The IVDR (Regulation (EU) 2017/746) replaced the old IVD Directive and introduced a strict, risk‑based classification system.
Devices are grouped into four classes, from lowest to highest risk:

• Class A – General laboratory equipment, instruments, specimen receptacles.
• Class B – Devices for lower‑risk conditions (e.g., pregnancy tests, cholesterol tests, fertility tests, drug‑of‑abuse screening when not for self‑testing).
• Class C – Devices for serious diseases, infectious diseases without life‑threatening risk, companion diagnostics, and many self‑testing kits.
• Class D – Highest risk, such as tests for transmissible agents that pose a high risk of death (e.g., HIV, hepatitis B, SARS‑CoV‑2) or blood grouping.

A lateral flow immunoassay automatically falls into a risk class determined by its intended purpose.
The old notion of a “low‑risk” Class 1 for all pregnancy or drug screens is no longer valid.

Why the “Class 1” Terminology Persists

The primary reference uses “Class 1, Class 2A, Class 2B” and treats self‑testing as a separate category.
That language actually mirrors the old Medical Device Directive (93/42/EEC), not any IVD regulation.
Under the IVDD, lateral flow tests like pregnancy kits and drug screen strips were classified simply as General IVDs, and they followed a manufacturer self‑declaration route very similar to what you described.

Many industry documents still echo this outdated framework.
Once you understand that mismatch, you can map the real classification and pathway for your device under the IVDR.

The CE Marking Pathway for Lowest‑Risk IVDs (Self‑Certification)

When Does Self‑Certification Actually Apply?

A genuine self‑certification route still exists under the IVDR, but it is exclusively for Class A devices.
Class A devices are typically instruments, general laboratory equipment, specimen collection tubes, and similar hardware—not finished diagnostic test kits that produce a patient result.

Because lateral flow immunoassays are nearly always reagent‑based tests that provide a clinical result, they are not Class A.
This means the “technical file → AR → Declaration of Conformity → CE mark” path you described is not the full picture for a lateral flow assay under current law.

The Self‑Certification Steps (For Context, Under the IVDD)

If your device indeed qualified under the old IVDD as a General IVD, the process you mentioned was accurate.
For completeness, here is that legacy pathway, adapted from your references:

1. Technical File Compilation
   Gather design documentation, manufacturing test reports, operating instructions, and evidence that the assay meets the essential safety and performance requirements.

2. Appoint a European Authorized Representative
   Designate a physical entity in the EU/EEA. This AR registers the device with the relevant national Competent Authority and acts as your regulatory contact.

3. Draft and Sign a Declaration of Conformity
   Prepare a legally binding declaration stating the product complies with all applicable regulatory standards.

4. Affix the CE Mark
   Once the above steps are complete, place the CE mark on the product packaging and ship into the EU market.

Under the IVDR, even Class A devices follow a similar high‑level outline, but for any lateral flow test that is Class B or above, these steps are incomplete without the intervention of a Notified Body.

Bringing a Lateral Flow Test to Market Under the IVDR: Practical Realities

Most Lateral Flow Tests Are Class B (or Higher)

A lateral flow immunoassay is classified based on its intended purpose and the user setting.
Common examples:

• Pregnancy test (self‑testing) → Class B (specific exemption in IVDR Annex VIII, Rule 5).
• Pregnancy test (professional use) → Class B.
• Drug‑of‑abuse screen (professional use) → Typically Class B, unless the drug misuse poses a high public health risk; then it can rise to Class C.
• Drug‑of‑abuse screen (self‑testing) → Class C (self‑test rule).
• Infectious disease lateral flow (e.g., influenza, Streptococcus A) → Class C, because it detects a transmissible agent that is not life‑threatening per the classification rules.
• HIV, hepatitis, or similar high‑risk transmissible agents → Class D.

None of these are Class A.
Self‑certification without a Notified Body is therefore not an option for a new lateral flow device intended for the EU market.

The Role of a Notified Body for Class B and Above

For a Class B device, the conformity assessment route under the IVDR involves Annex IX (Quality Management System) plus Annex XI (Production Quality Assurance), or alternative combinations.
In every case, a Notified Body must review your technical documentation, audit your QMS, and issue a certificate before you can issue a Declaration of Conformity.

This is fundamentally different from the simple registration‑only process.
You still need an Authorized Representative and a technical file, but the Notified Body acts as the gatekeeper, and timelines and costs increase substantially.

Common Pitfalls and Trade‑offs

Ignoring the IVDR’s actual classification rules is the single biggest risk.
Here are the key trade‑offs to keep in mind.

• Misclassification Risk
  Treating a lateral flow test as “Class 1” or “General IVD” under IVDR can lead to immediate market withdrawal, loss of CE marking privilege, and legal liability. Validate your class with a regulatory expert before any submission.

• Increased Technical Documentation Burden
  Under the IVDR, the technical file for a Class B+ device must include comprehensive clinical evidence, a performance evaluation plan, and post‑market surveillance. This goes far beyond the basic documentation that sufficed under the IVDD.

• Language and Labeling Requirements
  Self‑testing and near‑patient devices often require IFUs in the languages of each Member State. That’s a logistical layer on top of the core regulatory steps.

• Transitional Provisions for Legacy Devices
  If your lateral flow test already held a valid CE certificate under the IVDD, you may benefit from the extended transition periods (until 2029, under certain conditions). This allows you to continue selling without immediate IVDR certification, but only if you avoid significant design changes.

Making the Right Choice for Your Product Strategy

Your pathway depends entirely on whether your device is a legacy product or a new development.
Use the following goals to guide your approach.

• If you hold a valid IVDD CE certificate for a pregnancy or drug‑screen lateral flow test: Focus on leveraging transitional provisions while working on your IVDR‑compliant technical documentation and QMS. A Notified Body will eventually be required.

• If you are developing a new lateral flow immunoassay for the EU market: Abandon any “Class 1” or “self‑certification” assumption. Determine the accurate IVDR class (likely B or C) and start building a Notified Body‑ready Quality Management System from day one.

• If your primary focus is the lowest possible regulatory burden: A self‑certification route is only possible if your device is truly Class A—for example, a specimen collection cup, not a finished test kit. For anything that performs a measurement and delivers a result, prepare for Notified Body involvement.

• If you are an Authorized Representative or distributor reviewing a client’s product: Verify the IVDR classification directly against Annex VIII. Do not rely on legacy “Class 1” claims in marketing materials; insist on seeing the EU certificate or the Declaration of Conformity matched to the correct regulatory pathway.

Align your regulatory strategy with the true risk class from the start, and you turn a complex regulation into a structured, manageable plan.

Summary Table:

Navigating EU IVDR compliance while developing market-ready lateral flow assays requires reliable components and regulatory precision. CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to premium IVD raw materials, technical services, and consulting—covering every stage from concept to clinic.

Accelerate your assay performance and transition seamlessly to full regulatory compliance. Contact CamelBio today to speak with our technical experts!